AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...

A new blood test is designed to find mold infections deep inside the body, sparing patients from tissue biopsies.

You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Vincent Bagambe, Director of Planning and Strategic Information at UAC, warned that the withdrawal of U.S. funding could ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...